【摘要】 目的分析聚乙二醇化干扰素(PegIFN)联合利巴韦林治疗对慢性丙型肝炎的疗效及影响因素。方法使用聚PegIFNα-2a(派罗欣180μg/周)联合利巴韦林(根据体重900~1200 mg/d)治疗60例慢性丙型肝炎患者,疗程48周。结果本研究60例慢性丙型肝炎患者中,HCV-Ⅰ型45例,占75%,非HCV-Ⅰ型15例,占25%。HCV-Ⅰ型和非HCV-Ⅰ型患者持续应答(SVR)率分别为60.0%和93.3%,差异具有统计学意义(χ2=6.162,P=0.013);基线病毒载量,以HCV RNA定量1×106 IU/ml划分,HCV RNA高水平组和低水平组SVR分别为48.3%和77.3%,差异具有统计学意义(χ2=6.093,P=0.014)。治疗过程中获得快速病毒学应答(RVR)的病例获得SVR和未获得RVR的病例获得SVR的比率分别为84.6%和38.1%,差异具有统计学意义(χ2=9.690,P=0.002)。治疗过程中获得早期病毒学应答(EVR)的病例获得SVR和未获得EVR的病例获得SVR的比率分别为78.4%和11.1%,差异具有统计学意义(χ2=4.036,P=0.045)。结论慢性丙型肝炎患者的治疗过程中,病毒基因型、基线病毒载量以及治疗过程中是否获得RVR/EVR均可能影响治疗后的持续病毒学应答。更多还原

【Abstract】 Objective To analyze the clinical effects and the influence factors of combination of peg-interferon(PegIFN) and ribavirin in the treatment of patients with chronic hepatitis C(CHC). Methods Total of 60 patients with CHC received the combination therapy of pagasys(180 μg/week) and ribavirin(900-1200 mg/d) for 48 weeks. Results Among the 60 patients, 45(75%) were HCV-genotype-Ⅰ and 15(25%) were non-HCV-genotype-Ⅰ, and the sustained virological response(SVR) rates were 60% and 93.3%, respectively(χ2 = 6.162, P = 0.013). The baseline of HCV RNA level was defined by 1 × 106 IU/ml, and the SVR rates of high and low serum HCV RNA level groups were 48.3% and 77.3%, respectively(χ2 = 6.093, P = 0.014). The SVR rates of rapid virological response(RVR) obtained group and non-RVR obtained group were 84.6% and 38.1%, respectively(χ2 = 9.690, P = 0.002). The SVR rates of early virological response(EVR) obtained group and non-EVR obtained group were 78.4% and 11.1%, respectively(χ2 = 4.036, P = 0.045). Conclusions The SVR of the combination treatment in CHC patients could be influenced by the genotype, the baseline serum levels of HCV RNA and whether RVR/EVR obtained or not.更多还原